Table 2.
Associations between clinical factors and prevalent fracture
| Univariate analysis | Multivariate analysis* | |||||
|---|---|---|---|---|---|---|
| Clinical characteristic | Prevalent fracture (n=38) | No prevalent fracture (n=124) | OR (95% CI) | p-value | OR (95% CI) | p-value |
| Age in years, mean ± SD | 67 ± 14.6 | 55 ± 14.6 | 1.06 (1.03–1.10) | <0.0005 | 1.06 (1.03–1.10) | <0.0005 |
| Female, n (%) | 14 (37) | 49 (40) | 1.12 (0.53–2.37) | 0.77 | ||
| BMI (kg/m2), mean ± SD | 26 ± 4.5 | 26 ± 5.6 | 1.01 (0.94–1.09) | 0.82 | ||
| Diagnosis, n (%) | ||||||
| • DLBCL | 32 (84) | 112 (90) | ref. | |||
| • Other | 6 (16) | 12 (10) | 1.75 (0.61–5.03) | 0.30 | ||
| Ann Arbor Stage, n (%) | ||||||
| • Stage I–II | 16 (42) | 59 (48) | ref. | ref. | ||
| •Stage III–IV | 22 (58) | 65 (52) | 1.25 (0.60–2.60) | 0.55 |
1.19 (0.53–2.68) |
0.68 |
| IPI score, n (%) | ||||||
| • 0–1 (low risk) | 8 (22) | 53 (45) | ref. | |||
| • 2–5 (intermediate to high risk) | 28 (78) | 64 (55) | 2.90 (1.22–6.90) | 0.02 | ||
| LDH, mean ± SD | 334 ± 257 | 398 ± 965 | 1.00 (1.00–1.00) | 0.71 | 1.00 (1.00–1.00) | 0.77 |
| Bone marrow involvement, n (%) | 8 (22) | 23 (19) | 1.18 (0.48–2.91) | 0.73 | ||
| Prior diagnosis of osteoporosis, n (%) | 2 (5) | 3 (3) | 2.23 (0.36–13.87) | 0.39 | ||
| Bone active medications, n (%) | ||||||
| • Vitamin D | 4 (11) | 20 (16) | 0.61 (0.20–1.92) | 0.40 | ||
| • Calcium | 5 (13) | 15 (12) | 1.10 (0.37–3.26) | 0.86 | ||
| • Bisphosphonate | 1 (3) | 2 (2) | 1.65 (0.15–18.70) | 0.69 | ||
OR odds ratio, CI confidence interval, SD standard deviation, BMI body mass index, DLBCL diffuse large B-cell lymphoma, IPI International Prognostic Index, LDH lactate dehydrogenase
*Because the variables significant at p<0.05 in univariate analysis (age and IPI) are not independent, multivariate logistic regression was performed with the available components of the IPI score (age, stage, LDH) instead
Statistically significant ORs with p-value <0.05 are italicized for emphasis